Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2
October 20th 2017Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).
Read More